On August 11, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL gene-silencing technology, reported the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the Company’s intellectual property portfolio.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The patent allowance represents a critical milestone in protecting Phio’s strategic interest in the Company’s INTASYL platform. PH-894, designed to selectively silence BRD4, is a key regulator of gene expression associated with proliferative and infectious disease.
"Robust intellectual property protection is a continuous focus in our development strategy to advance novel immuno-oncology therapies and maximize the long-term value of the INTASYL platform," said Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals. "This patent advancement solidifies our commitment to advance PH-894 in the U.S. and pursue strategic collaborations internationally."
Phio has built a comprehensive patent estate supporting its INTASYL technology and therapeutic pipeline. The Company’s portfolio currently includes 54 issued patents covering INTASYL chemistry, specific gene targets, immuno-oncology compounds, and therapeutic applications across major global markets.
The newly allowed patent further reinforces Phio’s commitment to protecting its proprietary innovations and advancing next-generation cancer therapies based on targeted gene silencing.
(Press release, Phio Pharmaceuticals, AUG 11, 2026, View Source [SID1234669965])